Quest Journals
Journal of Research in Pharmaceutical Science
Volume 9 ~ Issue 8 (2023) pp: 14-20
ISSN(Online) : 2347-2995
www.questjournals.org

Research Paper

Symphony of Science: Harmonizing Randomization Procedures Across Clinical Trial Phases

Dhanshree .M. Joshi[1]
[1]PG student,Clinical Research, School of Allied Health Sciences, Datta Meghe Institute OfHigher Education And Research, Sawangi Meghe, Wardha

Vaishnavi Ajankar[2]
[2]PG student,Clinical Research, School of Allied Health Sciences, Datta Meghe Institute Of Higher Education And Research, Sawangi Meghe, Wardha

Srushti Thakare[3]
[3]PG student,Clinical Research, School of Allied Health Sciences, Datta Meghe Institute Of Higher Education And Research, Sawangi Meghe, Wardha

Sejal Patil[4]
[4]PG student,Clinical Research, School of Allied Health Sciences, Datta Meghe Institute Of Higher Education And Research, Sawangi Meghe, Wardha

Shraddha Banmare[5]
[5]PG student,Clinical Research, School of Allied Health Sciences, Datta Meghe Institute Of Higher Education And Research, Sawangi Meghe, Wardha

Kalyani Kshirsagar[6]
[6]PG student,Clinical Research, School of Allied Health Sciences, Datta Meghe Institute Of Higher Education And Research, Sawangi Meghe, Wardha

Sweza Bhaisare[7]
[7]PG student,Clinical Research, School of Allied Health Sciences, Datta Meghe Institute Of Higher Education And Research, Sawangi Meghe, Wardha

Amruta Dadmal[8]
[8]PG student,Clinical Research, School of Allied Health Sciences, Datta Meghe Institute Of Higher Education And Research, Sawangi Meghe, Wardha

Abstract:-
Clinical research is a comprehensive investigation in assessing the safety and effectiveness of a new drug. Clinical research constitutes approximately three important stages for bringing a new drug to market such as; Drug discovery, pre-clinical testing, and, clinical trials. Clinical trials are conducted to check the safety and efficacy of the drug through systematic Good clinical practices guidelines. The clinical trial is performed in human subjects and intended to discover or verify the clinical, pharmacological, and other pharmacodynamic effects of an investigational product or new drug. The trial is conducted in phases I- IV among human subjects whereas, Phase 0 is the preclinical or animal testing phase in the clinical trial process and Phase V is the phase in which data is collected which is being gathered in all the human trial phases i.e. from phases I-IV.The human participants are involved in Phase I in a small number, the number of participants increased as the drug passes from phase I to phase II- phase IV. The allocation of human subjects in phases is done through a method known as randomization. Abrief description of clinical trial phases since 0-V and the different types of randomization procedure is explained in the below article.

Keywords:-
Clinical research, New drugs, Phases, Human subjects, Allocation procedure, Animal testing, Randomization.

Received 15 August, 2023; Revised 28 August, 2023; Accepted 31 August, 2023 *Published with open access at **www.questjournals.org***

I. Introduction:-

Clinical trials constitute a vital facet of health research and scientific exploration, elucidating essential systematic contributions. The imperative for systematic research extends across various scientific domains, serving as the cornerstone for advancement. This universal recognition underscores the pivotal role research assumes in driving progress across scientific disciplines. At its core, research serves as the crucible in which questions find answers and novel insights are unearthed. Its pervasive significance remains evident across the scientific spectrum, constituting the principal approach employed to illuminate and expand our comprehension of the intricacies of the world around us. (1)Clinical trial phases encompass a sequential series, denoted as phases 0 through V, which collectively investigate the potential benefits or harms of an intervention in human subjects(2)

- Phase 0 clinical trial / Preclinical phase:-

Phase 0 involves determining the pharmacodynamics and pharmacokinetics (2) At the outset of clinical research, IND exploratory investigations, also referred to as phase 0 studies, entail the exposure of a small cohort of human subjects to minimal doses of a compound, devoid of therapeutic or diagnostic intent. Clinical investigators closely monitor a group of approximately 10 study participants over a brief period, generally lasting less than a week. These preliminary investigations precede the conventional assessments of dose escalation, safety, and tolerance, serving a distinct purpose. It's important to note that these studies do not supplant phase I clinical trials, nor do they provide evidence of a medication's efficacy in addressing a specific pathology. Instead, prior to embarking on phase 1 trials, these investigations play a pivotal role in the early screening of potential drug candidates, aiding in the exclusion of substances with limited potential (3).
The purpose of conducting these trials is to expedite the drug development process by reducing the critical path, examining the pharmacokinetic and pharmacodynamic behaviors of investigational new drugs (INDs) in human subjects, facilitating the rapid identification of favorable drug candidates, and ultimately cutting down on both development time and expenses. However, these trials are not driven by therapeutic intent, which can lead to challenges in motivating patient participation. Moreover, there's a potential risk of delaying or excluding patients from other clinical trials with genuine therapeutic aims. Additionally, concerns arise regarding the applicability of micro-dosing pharmacokinetics to therapeutic dosing and the availability of sufficiently sensitive analytical techniques (4).

- Phase I clinical trial:-

Phase I clinical trials aim to evaluate essential parameters such as the optimal administration route, frequency, dosage, maximum tolerated dose (MTD), and potential side effects of a new treatment. These trials extensively analyze safety, pharmacokinetics, and pharmacodynamics. The pivotal objective is to ascertain the treatment's safety profile. These trials typically involve 20 to 100 participants and are under the vigilant oversight of clinical investigators.In the absence of significant adverse reactions, the dosage is incrementally increased, while simultaneously assessing the participants' responsiveness to the treatment. This graduated dosage escalation strategy aids in determining the most effective and safest dose feasible for administration, which is a mere fraction of the doses causing harm in preclinical animal testing. The primary focal point of phase I trials is to subject participants to subtherapeutic doses only when safety is firmly upheld, allowing for a swift and secure progression.While healthy volunteers generally constitute the bulk of participants, certain trials may necessitate the inclusion of patients afflicted with specific medical conditions (2).

- Phase II clinical trial:-

Phase I/II dose-finding studies are aimed at identifying the optimal dosage (Maximum Safe Dose or MSD) that achieves both maximal therapeutic response and minimal toxicity risk. In Phase I clinical trials, the focus lies on establishing the Best Achievable Dose (BAT), while Phase II trials delve into assessing potential efficacy and robustly illustrating treatment benefits for the targeted disease. It is crucial that the intervention lacks any therapeutic impact. These investigations are conducted on larger cohorts (typically 100-300 participants) to gauge drug effectiveness and conduct thorough safety assessments. The doses derived from the initial phase are administered, followed by meticulous patient monitoring under the guidance of the clinical investigator. Typically, these trials are carried out within a multi-institutional framework (2).

- Phase III clinical trial:-

Phase III trials represent the pinnacle of scientific clinical investigation for new therapies, aiming to meticulously compare their efficacy against established treatments. Operating as the premier "premarketing phase" of clinical trials, these endeavors stand as the most exhaustive and rigorous evaluations of novel therapies. However, they also manifest as the most resource-intensive and time-demanding trials in the clinical research landscape. The intricacies of their design and execution can present challenges, encompassing recruitment of substantial participant cohorts ranging from 100 to 3000 individuals. Within these trials, diverse methodologies such as randomized controlled trials (including parallel designs), uncontrolled trials focusing on single treatments (monotherapy), reliance on historical data for comparison, non-randomized parallel trials, factorial designs, and sequential approaches are harnessed. Vigilant oversight by both clinical investigators and private physicians ensures the comprehensive monitoring of patients throughout the trial's course (2).

- Phase IV clinical trial:-

Phase IV studies encompass all investigations, excluding routine monitoring, conducted subsequent to drug approval, specifically addressing the sanctioned usage. These post-marketing surveillance studies are oriented towards evaluating the drug's real-world functionality. They extend their reach to encompass any individual seeking medical intervention, overseen by their attending physician who meticulously gauges the treatment's outcomes. The primary objectives of these trials encompass evaluating efficacy, uncovering infrequent prolonged adverse effects within expansive populace cohorts and extended timeframes, scrutinizing healthcare expenses and consequences, and delving into pharmacogenetic intricacies. In certain cases, a drug might even pave the way for novel clinical applications, engaging a substantial patient pool and involving numerous healthcare practitioners (5).

- Phase V clinical trials:-

This translational research endeavor seeks to transition from laboratory experimentation to practical application at the patient's bedside. Phase V clinical trials encompass comparative efficacy investigations and community studies. The focus lies on scrutinizing the accumulated data and assessing the entirety of the reports. Patient monitoring is not part of the protocol. The primary goal is to pinpoint novel therapies for seamless integration into widespread clinical implementation. Categorized under Cornell Cooperative Extension and labeled with tags like Cooperative Extension program, evidence-based program, research evaluation, research methods, and research translation, this initiative operates within the realms of Evidence-based living and learning centers (2).

The concept of randomization, often referred to as a "randomized controlled trial" (RCT), pertains to a clinical investigation where participants are assigned to different treatment groups through a random process. This allocation is unpredictable, ensuring that each participant holds an equal and recognized chance of being placed within a specific group. The randomized experimental design stands out as the preferred methodology for research, offering the highest level of control over the study. This design empowers researchers to draw causal conclusions with the utmost confidence when assessing treatment effects in health research. While real-world clinical tests cannot address every potential confounding factor, the RCT design delivers the most compelling evidence regarding the impact of one variable on another (6).

The commencement of the 20th century marked the initial stages of the increasing adoption of randomized controlled trials (RCTs) within healthcare research. Originating in the 1920s, the randomized controlled trial emerged as a novel experimental design approach and swiftly evolved into a fundamental fixture of scientific methodology (7). Subsequently, during the 1940s, the RCT design gained notable endorsement within the realm of medicine. Once the outcomes were disseminated, randomization garnered acknowledgment as a robust experimental framework for mitigating bias in inter-group comparisons. These endeavors culminated in the adoption of random allocation as a standard practice in experimental trials (8).

Randomizationis the process of allocating participants to treatment and control groups under the assumption that each participant has an equal probability of being assigned to any group(9)Researchers employ randomization for various reasons. Notably, it serves to eliminate systematic discrepancies among individuals in diverse groups. Any consistent dissimilarities among these groups could unduly sway the findings of a clinical trial. For instance, envision a study assessing the efficacy of a walking intervention, where volunteers are sorted into control and treatment factions. If a disproportionate number of elderly individuals wind up in the treatment group, the outcomes of the walking intervention could potentially be influenced by this disparity. To ensure an unbiased inference, it becomes imperative for the investigator to incorporate covariate adjustments in the analysis. This adjustment is crucial as it disentangles the genuine effects of the therapy from the repercussions of the uneven distribution of variables(10) Furthermore, robust randomization ensures that the allocation of individuals into groups remains unpredictable beforehand (referred to as allocation concealment). Essentially, this means that neither the researchers, the participants, nor any other party should possess foreknowledge of a participant's group placement. Acquiring such information about group assignment introduces a potential source of bias that could compromise the integrity of the results (9)To achieve random allocation of individuals across treatment groups in clinical trials, researchers have proposed a variety of methods. These encompass simple randomization, block randomization, stratified randomization, and covariate adaptive randomization, among others, each offering distinct advantages and disadvantages. It is of paramount importance to select an appropriate method that yields data integrity and facilitates meaningful interpretation for your research study(9). Randomization offers three key benefits;

- First, it removes discrimination in the selection of treatments (selection bias)
- Second, random assignment makes it easier to hide the identification of treatments from researchers, participants, and judges
- Third, the use of probability theory is made possible by randomization, which enhances the likelihood that changes in the dependent variable are caused by the independent variables rather than by extraneous factors or confounding variables, reducing the likelihood of confounding bias(6)



(11)

Figure 1

- Figure 1 describes the random sampling in a clinical trial among a certain group of the population

Types of randomization techniques are: -

- **<u>Simple Randomization: -</u>**

Simple randomization is randomization based on a single sequence of random assignments(6)Among allocation strategies, none can rival the bias mitigation and complete unpredictability inherent in simple randomization for assigning interventions. Through this method, a sample is assembled in a manner ensuring that any distinct subset of identical size within a population possesses an equal opportunity of being distributed across different groups(7)This approach achieves a completely arbitrary allocation of individuals to specific groups. A common and foundational form of simple randomization involves coin tossing, where the outcome of each participant's assignment hinges on the coin's outcome (e.g., heads for control, tails for treatment) in cases with two treatment groups. Other methods include rolling a die (e.g., values equal to or below 3 for control, values over 3 for treatment), or utilizing a shuffled deck of cards (e.g., even-numbered cards for control, odd-numbered cards for treatment). For a straightforward participant randomization process, an alternative is using a random number table found in statistics books or generating random numbers through a computer (9).

This randomization approach lends itself to easy implementation in clinical research. Particularly in extensive clinical studies, simple randomization can be a dependable method for achieving a roughly equitable distribution of individuals across groups. Nonetheless, when dealing with clinical research characterized by a comparatively modest sample size, the outcomes of randomization might present challenges, potentially resulting in an uneven allocation of participants among the groups (6).



(12) TOSS THE COIN (11) COMPUTER GENERATED

Figure 2 **Figure 3**

- **Block Randomization: -**

To enhance the balance between study arms and mitigate the risks of bias and confounding, a swift approach is found in blocked randomization. This technique ensures an even allocation of participants to each treatment group by employing random assignment within defined blocks. For example, when there's a desire to distribute participants evenly in sets of four, there exist six possible ways to achieve this distribution. Subsequently, the succeeding block of participants is randomly placed into research groups following one of these pre-established orders. If the overall sample size surpasses the product of block size and the number of orderings, the potential for repeating blocks emerges. Moreover, it's crucial that the block size be divisible by the number of study groups (13).



Figure 5 (14)

- **Stratified randomization:-**

Stratified randomization is a dual-phase approach within clinical trials, involving the categorization of patients based on pertinent clinical attributes influencing outcome risk. Once stratified, patients are subsequently allocated to treatments through an individualized randomization scheme applicable to each stratum (15).



Figure 6 (16)

- **Unequal randomization:-**

Unequal distribution in ratios greater than 1:1 or 1:1:1. The overall proportion of the studies using unequal randomization in three-arm studies is similar to that of two-arm studies(17)

Figure 7 (18)

- **Adaptive randomization:-**

An adaptive randomization design involves adjusting randomization schedules to accommodate varying and potentially unequal probabilities of assigning treatments, with the aim of augmenting the likelihood of achieving successful outcomes (19). A frequently employed approach within adaptive randomization is treatment-adaptive randomization (20), covariate-adaptive randomization, and response-adaptive randomization (21). While the utilization of an adaptive randomization design, often referred to as "play-the-winner," has the potential to enhance the likelihood of achieving successful outcomes, its practicality becomes limited when dealing with extensive trials or those involving prolonged treatment periods. This limitation arises from the interdependence of subject randomization on the responses of prior subjects. Consequently, employing an adaptive randomization approach in large or long-duration trials significantly extends the trial's completion time. Furthermore, the predetermined randomization schedule might not be accessible before the study commences. Moreover, obtaining accurate statistical insights into the treatment's effectiveness becomes challenging, if not unattainable, due to the intricate probability structure resulting from the application of adaptive randomization (19).



(19) **Figure 8**

II. Conclusion:-

As the prevalence of various diseases continues to rise, posing significant threats to human health, the demand for novel drug development has become more pressing than ever. Global pharmaceutical industries are taking significant strides in the field of drug development, introducing improved medications aimed at safeguarding human well-being through rigorous clinical trials and research processes. Therefore, it becomes imperative to delve into the realm of clinical trials and their methodologies, elucidating the imperative behind novel drug creation to benefit humanity. Among the array of procedures inherent in these phases, randomization stands out as a pivotal approach facilitating the controlled implementation of investigational products in human subjects. The adoption of randomization protocols serves a dual purpose: upholding the utmost confidentiality between trial participants and ensuring adherence to the essential guidelines governing each member's involvement in the clinical trial proceedings.

REFERENCES:-

[1]. Marczyk GR, DeMatteo D, Festinger D. Essentials of research design and methodology. John Wiley & Sons; 2010 Jun 3.

[2]. Mahan VL. Clinical trial phases. International Journal of Clinical Medicine. 2014 Dec 29;5(21):1374-83. https://www.scirp.org/html/5-2101019_52733.htm

[3]. Marchetti S, Schellens JH. The impact of FDA and EMEA guidelines on drug development in relation to Phase 0 trials. British Journal of Cancer. 2007 Aug;97(5):577-81. https://www.nature.com/articles/6603925

[4]. Le Tourneau C, Lee JJ, Siu LL. Dose escalation methods in phase I cancer clinical trials. JNCI: Journal of the National Cancer Institute. 2009 May 20;101(10):708-20. https://doi.org/10.1093/jnci/djp079

[5]. Bernabe RD, Van Thiel GJ, Raaijmakers JA, Van Delden JJ. The fiduciary obligation of the physician-researcher in phase IV trials. BMC Medical Ethics. 2014 Dec;15:1-8. https://link.springer.com/article/10.1186/1472-6939-15-11

[6]. Baghbaninaghadehi F, Armijo-Olivo S, Woodhouse L. Fundamentals of randomization in clinical trial. IJANHS. 2016 Feb 22;4(1):174-87. : http://medical.cloud-journals.com/index.php/IJANHS/article/view/Med-276

[7]. Cox DR, Reid N. The theory of the design of experiments. CRC Press; 2000 Jun 6. https://www.google.co.in/books/edition/The_Theory_of_the_Design_of_Experiments/a_vKBQAAQBAJ?hl=en&gbpv=0

[8]. Schulz KF, Grimes DA. Generation of allocation sequences in randomised trials: chance, not choice. The Lancet. 2002 Feb 9;359(9305):515-9. https://doi.org/10.1016/S0140-6736(02)07683-3

[9]. Kang M, Ragan BG, Park JH. Issues in outcomes research: an overview of randomization techniques for clinical trials. Journal of athletic training. 2008 Mar 1;43(2):215-21. **https://doi.org/10.4085/1062-6050-43.2.215**

[10]. Kalish LA, Begg CB. Treatment allocation methods in clinical trials: a review. Statistics in medicine. 1985 Apr;4(2):129-44.**https://doi.org/10.1002/sim.4780040204**

[11]. randomization method image - Google Search [Internet]. [cited 2023 Feb 4]. Available from: https://www.google.com/search?q=+randomization+method+image&tbm=isch&ved=2ahUKEwi3xdrusvv8AhV1UnwKHcEPA0oQ2-cCegQIABAA&oq=+randomization+method+image&gs_lcp=CgNpbWcQAzoECCMQJ1DeDljIE2D8GGgAcAB4AYAB-wGIAa4JkgEFMC40LjKYAQCgAQGqAQtnd3Mtd2l6LWltZ8ABAQ&sclient=img&ei=ZxDeY_f1O_Wk8QPBn4zQBA&bih=569&biw=1280&rlz=1C1VDKB_enIN1040IN1040#imgrc=ei6YpgviUZq58M

[12]. randomization toss a coin method image - Google Search [Internet]. [cited 2023 Feb 4]. Available from: https://www.google.com/search?q=randomization+toss+a+coin+method+image&tbm=isch&ved=2ahUKEwiMhpqMtPv8AhUPKbcAHUGPBNcQ2-cCegQIABAA&oq=randomization+toss+a+coin+method+image&gs_lcp=CgNpbWcQA1AAWMQZYPceaABwAHgBgAGvBIgB7haSAQkwLjQuNy4
1LTGYAQCgAQGqAQtnd3Mtd2l6LWltZ8ABAQ&sclient=img&ei=shHeY4zlEI_S3LUPwZ6SuA0&bih=569&biw=1280&rlz=1C1VDKB_enIN1040IN1040#imgrc=V4e57rJyqWv0cM

[13]. Efird J. Blocked randomization with randomly selected block sizes. International journal of environmental research and public health. 2011 Jan;8(1):15-20. **https://doi.org/10.3390/ijerph8010015**

[14]. https://www.google.com/search?q=block+randomization+image&rlz=1C1VDKB_enIN1040IN1040&oq=block+randomization+image&aqs=chrome..69i57j33i160l2.8931j0j15&sourceid=chrome&ie=UTF-8#imgrc=WDGf4QYoTfCNCM

[15]. Kernan WN, Viscoli CM, Makuch RW, Brass LM, Horwitz RI. Stratified randomization for clinical trials. Journal of clinical epidemiology. 1999 Jan 1;52(1):19-26. https://doi.org/10.1016/S0895-4356(98)00138-3

[16]. https://www.google.com/search?q=stratified+randomization+image&rlz=1C1VDKB_enIN1040IN1040&sxsrf=APwXEde5sOXCTcpwrFFro0tV65l3DOB_0w%3A1680237911897&ei=V2UmZLe8NrOI4-EPttaigAI&ved=0ahUKEwj3w4H_rYX-AhUzxDgGHTarCCAQ4dUDCA8&uact=5&oq=stratified+randomization+image&gs_lcp=Cgxnd3Mtd2l6LXNlcnAQAzIFCAAQogQyBQgAEKIEMgUIABCiBDIFCAAQogQyBQgAEKIEOgoIABBHENYEELADOgcIIxCwAhAnOgYIABAIEB46CAgAEAgQHhAPOggIABCKBRCGAzoICAAQCBAeEA06CggAEAgQHhANEA86CAgAEIkFEKIESgQIQRgAULUFWKo7YOpCaAFwAXgAgAHoAYgB3xWSAQYwLjE1LjGYAQCgAQHIAQjAAQE&sclient=gws-wiz-serp#imgrc=vOmD9DIi1YPZvM

[17]. Gupta S, Jain S, Yeh J, Guddati AK. Unequal allotment of patients in phase III oncology clinical trials. American Journal of Cancer Research. 2021;11(7):3735.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8332855/

[18]. https://www.google.com/search?q=unequal+randomization+image&rlz=1C1VDKB_enIN1040IN1040&sxsrf=APwXEddxQNl4l_aVb8i00OjE85R4tI2syg:1680245807977&source=lnms&tbm=isch&sa=X&ved=2ahUKEwiY6JO0y4X-AhWGV2wGHdLpCdkQ_AUoAXoECAEQAw&cshid=1680245881158798&biw=1280&bih=512&dpr=1.5#imgrc=-qawwferwsB-DM

[19]. Chow SC, Chang M. Adaptive design methods in clinical trials–a review. Orphanet journal of rare diseases. 2008 Dec;3(1):1-3.

[20]. Efron B. Forcing a sequential experiment to be balanced. Biometrika. 1971 Dec 1;58(3):403-17.

[21]. Rosenberger WF, Stallard N, Ivanova A, Harper CN, Ricks ML. Optimal adaptive designs for binary response trials. Biometrics. 2001 Sep;57(3):909-13.